$AMGN surges 8.15% to $368.75 52-week high on $200M inflows
$Amgen(AMGN)$
Amgen Inc.(AMGN) Skyrockets +8.15%: Bio-Tech Giant Touches 52-Week High, Momentum Accelerates
Latest Close Data:
AMGN closed at $366.20 on 2026-02-04, surging +8.15% ($27.61). The session high of $368.75 matched the 52-week high.
Core Market Drivers:
-
Strong buying momentum fueled by robust institutional and retail inflows, with net positive capital flow of ~$200M for the day.
-
The stock's breakout follows a period of consolidation, potentially driven by positive sentiment in the biotech sector and anticipation around the company's pipeline updates.
Technical Analysis:
-
The explosive move was confirmed by high volume (5.9M shares, Volume Ratio 2.11x) and strong momentum indicators.
-
The RSI(6) spiked to 76.71, indicating overbought conditions in the short term but confirming powerful bullish momentum.
-
The MACD (DIF: 5.72, DEA: 4.31, MACD: 2.82) shows a strong bullish crossover and expanding histogram, reinforcing the uptrend.
Key Price Levels:
-
Immediate Pivot/Support: $352.03 (Today's Open)
-
Primary Support: $342.38 (Today's Low)
-
Strong Resistance: $368.75 (52-Week & Today's High). A confirmed break above could open the path to $380+.
Valuation Perspective:
Trading at a Forward P/E of 15.26, which is slightly above its historical average of 14.56 but remains reasonable for a large-cap biotech with strong profitability (ROE: 81.71%).
Analyst Targets:
The consensus among 28 analysts is a "Buy" with an average price target of $341.83, which is now ~6.7% below the current price, suggesting potential for target upgrades.
Weekly Outlook:
Expect near-term consolidation or a pullback after the sharp rally, with initial support at $352. Sustained trading above $368.75 could target the $375-$380 zone in the coming sessions. Watch for a potential RSI cool-down.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
